Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...
Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...
GlobalData on MSN11h
Strong Wegovy revenue growth for Novo Nordisk but shares dipNovo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same ...
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated ...
Novo Nordisk is stealing the spotlight in the obesity drug market as Wegovy's sales skyrocketed by 76% year-over-year to DKK ...
Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but ...
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.
(RTTNews) - Novo Nordisk (NVO) reported net profit for the first nine months of 2024 of 72.76 billion Danish Kroner up from 61.72 billion Kroner in the prior year. On a per share basis, net income ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback